Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
5
|
Resverlogix Corp.
|
Jun 22, 2020 08:50AM
|
What about < median LDL-C, and NAFLD question?
|
4
|
Resverlogix Corp.
|
Jun 22, 2020 11:50AM
|
Re: What about < median LDL-C, and NAFLD question?
|
7
|
Resverlogix Corp.
|
Jun 22, 2020 12:14PM
|
Re: What about < median LDL-C, and NAFLD question?
|
7
|
Resverlogix Corp.
|
Jun 22, 2020 12:58PM
|
The more, the merrier
|
9
|
Resverlogix Corp.
|
Jun 22, 2020 01:20PM
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
10
|
Resverlogix Corp.
|
Jun 22, 2020 10:42PM
|
Re: Timelines
|
5
|
Resverlogix Corp.
|
Jun 24, 2020 05:27PM
|
Re: Recent paper - T2D and CHF
|
5
|
Resverlogix Corp.
|
Jun 24, 2020 07:05PM
|
NAFLD is going to get much worse
|
8
|
Resverlogix Corp.
|
Jun 25, 2020 10:59AM
|
Baricitinib restrains the immune dysregulation in COVID 19 patients
|
3
|
Resverlogix Corp.
|
Jun 30, 2020 06:59PM
|
New study in the Lancet regarding COVID 19 and blood clotting
|
3
|
Resverlogix Corp.
|
Jun 30, 2020 07:09PM
|
Re: New study in the Lancet regarding COVID 19 and blood clotting
|
2
|
Resverlogix Corp.
|
Jun 30, 2020 07:18PM
|
Re: Report of exempt distribution
|
5
|
Resverlogix Corp.
|
Jul 01, 2020 03:14PM
|
Restricted Share Units - approx. 5 million
|
5
|
Resverlogix Corp.
|
Jul 07, 2020 08:27AM
|
For Scientists - Nature article/study on epigenetic changes after kidney injury
|
8
|
Resverlogix Corp.
|
Jul 07, 2020 09:11AM
|
Re: Restricted Share Units - approx. 5 million
|
5
|
Resverlogix Corp.
|
Jul 07, 2020 12:22PM
|
Re: Resverlogix Secures One-Year Extension of Maturity Date of Debenture
|
6
|
Resverlogix Corp.
|
Jul 22, 2020 11:28AM
|
Eastern Capital - Expiration of warrants
|
2
|
Resverlogix Corp.
|
Jul 23, 2020 06:11PM
|
Report of Exempt Distribution - 23 Jul 2020
|
|
Resverlogix Corp.
|
Jul 28, 2020 11:18AM
|
Re: Report of Exempt Distribution - 23 Jul 2020
|
|
Resverlogix Corp.
|
Jul 28, 2020 12:00PM
|